Rapid Micro Biosystems rises as Samsung Biologics orders more automation systems

Rapid Micro Biosystems

12/03/2026 10:39

** Shares of drug manufacturing firm Rapid Micro Biosystems RPID.O rise 3% to $4.50 premarket

** Co says it won a new multi-system order from Samsung Biologics to deploy its Growth Direct platform

** Growth Direct automates microbial quality checks, helping drugmakers speed up safety testing for biologics and vaccines - RPID

** Order expands an existing partnership with Samsung Biologics, a major contract manufacturer for the pharma industry, co says

** CEO Robert Spignesi says the systems deliver faster results and higher accuracy as Samsung scales up manufacturing

** Shares up about three-fold in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))